Clinical Trial Update: Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

View source ↗

Summary

An extension study update assessing long-term outcomes from the CLS-AX CLS1002-101 trial in patients with neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• CLS-AX CLS1002-101

Snippet

Sponsor: Clearside Biomedical, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Status: COMPLETED | Results posted: 2024-03-04